down arrow

Avenue Therapeutics, Inc.

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US05360L3042
USD
0.80
-0.09 (-10.46%)

Dec 04

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

0.800.80

52 Week

0.172.23
Valuation
Technical
Day's Volume

CASH

2.08 k

Shareholding (Mar 2025)

FII

0.00%

Held by 2 FIIs

DII

99.57%

Held by 0 DIIs

Promoter

0.00%

How big is Avenue Therapeutics, Inc.?

22-Jun-2025

As of Jun 18, Avenue Therapeutics, Inc. has a market capitalization of 0.83 million, classifying it as a Micro Cap, with net sales of 0.00 million and a net profit of -13.71 million over the last four quarters. As of December 2024, the company has shareholder's funds of 2.80 million and total assets of 2.67 million.

Market Cap: As of Jun 18, Avenue Therapeutics, Inc. has a market capitalization of 0.83 million, classifying it as a Micro Cap.<BR><BR>Recent Quarterly Performance: For the latest four quarters ending in March 2025, December 2024, September 2024, and June 2024, the company reported net sales of 0.00 million and a net profit of -13.71 million.<BR><BR>Balance Sheet Snapshot: As of December 2024, Avenue Therapeutics, Inc. has shareholder's funds amounting to 2.80 million and total assets of 2.67 million.

Read More

What does Avenue Therapeutics, Inc. do?

22-Jun-2025

Avenue Therapeutics, Inc. is a pharmaceutical company developing intravenous Tramadol for post-operative pain management. It has a market cap of $0.83 million and reported a net profit loss of $2 million as of March 2025.

Overview: <BR>Avenue Therapeutics, Inc. is a pharmaceutical company focused on developing and commercializing intravenous (IV) Tramadol for the treatment of moderate to moderately severe post-operative pain, operating within the Pharmaceuticals & Biotechnology industry and classified as a micro-cap company.<BR><BR>Financial Snapshot: <BR>Most recent Net Profit: -2 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 0.83 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -1.00 <BR>Return on Equity: -393.59% <BR>Price to Book: 0.24<BR><BR>Contact Details: <BR>Address: 2 Gansevoort St Fl 9, NEW YORK NY: 10014-1667 <BR>Tel: 1 781 6524500 <BR>Fax: 1 302 5313150 <BR>Website: http://www.avenuetx.com/

Read More

Who are in the management team of Avenue Therapeutics, Inc.?

22-Jun-2025

As of March 2022, Avenue Therapeutics, Inc.'s management team includes Dr. Lindsay Rosenwald (Executive Chairman), Dr. Lucy Lu (President and CEO), Dr. Jaideep Gogtay, Ms. Garrett Ingram, Mr. Neil Herskowitz, and Dr. Jay Kranzler (all Directors). They oversee the company's strategic direction and operations.

As of March 2022, the management team of Avenue Therapeutics, Inc. includes the following members:<BR><BR>- Dr. Lindsay Rosenwald, who serves as the Executive Chairman of the Board.<BR>- Dr. Lucy Lu, who is the President, Chief Executive Officer, and a Director.<BR>- Dr. Jaideep Gogtay, who is a Director.<BR>- Ms. Garrett Ingram, who is a Director.<BR>- Mr. Neil Herskowitz, who is an Independent Director.<BR>- Dr. Jay Kranzler, who is also an Independent Director. <BR><BR>This team is responsible for guiding the strategic direction and operations of the company.

Read More

Is Avenue Therapeutics, Inc. overvalued or undervalued?

20-Sep-2025

As of August 14, 2025, Avenue Therapeutics, Inc. is rated as risky due to overvaluation and poor financial metrics, including a Price to Book Value of 0.24, an EV to EBITDA ratio of 0.28, and a troubling ROE of -393.59%, alongside a year-to-date stock return of -57.50% compared to the S&P 500's 12.22%.

As of 14 August 2025, the valuation grade for Avenue Therapeutics, Inc. has moved from does not qualify to risky, indicating a significant downgrade in its investment appeal. The company appears to be overvalued, given its negative financial metrics, including a Price to Book Value of 0.24 and an EV to EBITDA ratio of 0.28. Additionally, the Return on Equity (ROE) is alarmingly low at -393.59%, highlighting severe profitability issues.<BR><BR>In comparison to its peers, Avenue Therapeutics has a P/E ratio of -0.3745, while Fresh Tracks Therapeutics, Inc. has a P/E of 0.8418, indicating that Avenue is lagging behind in valuation metrics. Furthermore, Pulmatrix, Inc. shows a more negative EV to EBITDA ratio of -1.4762, suggesting that Avenue's valuation is less favorable in the context of its industry. Notably, the company's stock has underperformed significantly, with a year-to-date return of -57.50% compared to the S&P 500's 12.22%, reinforcing the notion that it is overvalued in the current market environment.

Read More

Is Avenue Therapeutics, Inc. technically bullish or bearish?

20-Sep-2025

As of September 10, 2025, Avenue Therapeutics, Inc. shows a mildly bullish technical trend, supported by weekly MACD and KST indicators, despite some bearish signals from the RSI and moving averages, and has significantly underperformed the S&P 500 with a return of -68.52% over the past year.

As of 10 September 2025, the technical trend for Avenue Therapeutics, Inc. has changed from sideways to mildly bullish. The weekly MACD and KST indicators are both mildly bullish, while the monthly MACD and KST also indicate mild bullishness. However, the weekly RSI is bearish, and the daily moving averages are mildly bearish. The Bollinger Bands show a bullish stance on the weekly but are mildly bearish on the monthly. According to Dow Theory, there is no trend on the weekly but a mild bullish trend on the monthly.<BR><BR>In terms of performance, the stock has significantly underperformed the S&P 500 over the past year, with a return of -68.52% compared to the S&P 500's 17.14%. Overall, the current technical stance is mildly bullish, driven primarily by the weekly MACD, KST, and Bollinger Bands, despite some bearish signals from the RSI and moving averages.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
1

Poor Management Efficiency with a low ROCE of 0%

  • The company has reported losses and also has negative networth. This is not a good sign for the investors. Either company will have to raise fresh capital or report profits to sustain going forward
2

Poor long term growth as Net Sales has grown by an annual rate of 19.14% over the last 5 years

 
3

Positive results in Jun 25

4

Risky - Negative EBITDA

5

Majority shareholders : Mutual Funds

 
6

Underperformed the market in the last 1 year

stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 2 Million (Micro Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.82

stock-summary
Return on Equity

-153.33%

stock-summary
Price to Book

0.57

Revenue and Profits:
Net Sales:
1 Million
(Quarterly Results - Jun 2025)
Net Profit:
0 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
45.43%
0%
45.43%
6 Months
207.69%
0%
207.69%
1 Year
-57.22%
0%
-57.22%
2 Years
-94.44%
0%
-94.44%
3 Years
-45.95%
0%
-45.95%
4 Years
-99.95%
0%
-99.95%
5 Years
-99.98%
0%
-99.98%

Avenue Therapeutics, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News

Is Avenue Therapeutics, Inc. technically bullish or bearish?

As of 10 September 2025, the technical trend for Avenue Therapeutics, Inc. has changed from sideways to mildly bullish. The weekly MACD and KST indicators are both mildly bullish, while the monthly MACD and KST also indicate mild bullishness. However, the weekly RSI is bearish, and the daily moving averages are mildly bearish. The Bollinger Bands show a bullish stance on the weekly but are mildly bearish on the monthly. According to Dow Theory, there is no trend on the weekly but a mild bullish trend on the monthly. In terms of performance, the stock has significantly underperformed the S&P 500 over the past year, with a return of -68.52% compared to the S&P 500's 17.14%. Overall, the current technical stance is mildly bullish, driven primarily by the weekly MACD, KST, and Bollinger Bands, despite some bearish signals from the RSI and moving averages....

Read More

Is Avenue Therapeutics, Inc. overvalued or undervalued?

As of 14 August 2025, the valuation grade for Avenue Therapeutics, Inc. has moved from does not qualify to risky, indicating a significant downgrade in its investment appeal. The company appears to be overvalued, given its negative financial metrics, including a Price to Book Value of 0.24 and an EV to EBITDA ratio of 0.28. Additionally, the Return on Equity (ROE) is alarmingly low at -393.59%, highlighting severe profitability issues. In comparison to its peers, Avenue Therapeutics has a P/E ratio of -0.3745, while Fresh Tracks Therapeutics, Inc. has a P/E of 0.8418, indicating that Avenue is lagging behind in valuation metrics. Furthermore, Pulmatrix, Inc. shows a more negative EV to EBITDA ratio of -1.4762, suggesting that Avenue's valuation is less favorable in the context of its industry. Notably, the company's stock has underperformed significantly, with a year-to-date return of -57.50% compared to t...

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
19.14%
EBIT Growth (5y)
7.27%
EBIT to Interest (avg)
-7.97
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.00
Sales to Capital Employed (avg)
0.35
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
18.99%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
0.24
EV to EBIT
0.28
EV to EBITDA
0.28
EV to Capital Employed
-2.67
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-393.59%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bullish
Mildly Bearish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Bearish
Dow Theory
No Trend
No Trend
OBV
Mildly Bullish
Mildly Bearish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 3 Schemes (0.43%)

Foreign Institutions

Held by 2 Foreign Institutions (0.0%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 104.17% vs -80.00% in Jun 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "1.40",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "0.30",
          "val2": "-2.80",
          "chgp": "110.71%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.10",
          "chgp": "-100.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "0.30",
          "val2": "-7.20",
          "chgp": "104.17%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "211.50%",
          "val2": "0.00%",
          "chgp": "21.15%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -11.43% vs -191.67% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-11.30",
          "val2": "-14.50",
          "chgp": "22.07%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-0.60",
          "val2": "3.90",
          "chgp": "-115.38%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-11.70",
          "val2": "-10.50",
          "chgp": "-11.43%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoYstock-summary
Jun'25
Jun'24
Change(%)
Net Sales
1.40
0.00
Operating Profit (PBDIT) excl Other Income
0.30
-2.80
110.71%
Interest
0.00
0.00
Exceptional Items
0.00
0.10
-100.00%
Consolidate Net Profit
0.30
-7.20
104.17%
Operating Profit Margin (Excl OI)
211.50%
0.00%
21.15%
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is 104.17% vs -80.00% in Jun 2024

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-11.30
-14.50
22.07%
Interest
0.00
0.00
Exceptional Items
-0.60
3.90
-115.38%
Consolidate Net Profit
-11.70
-10.50
-11.43%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -11.43% vs -191.67% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About Avenue Therapeutics, Inc. stock-summary
stock-summary
Avenue Therapeutics, Inc.
Pharmaceuticals & Biotechnology
Avenue Therapeutics, Inc. is a pharmaceutical company. The Company is focused on developing and commercializing its product principally for use in the acute/intensive care hospital setting. The Company’s product candidate is intravenous (IV) Tramadol, for the treatment of moderate to moderately severe post-operative pain. Tramadol, a synthetic dual-acting opioid, is a centrally acting analgesic with weak opioid agonist properties. It also works via the inhibition of serotonin and noradrenaline re-uptake and blocking nociceptive impulses at the spinal level. Its Oral tramadol is marketed in the United States for moderate to moderately severe pain in adults. Its Parenteral tramadol formulations include IV, intramuscular (IM), and subcutaneous (SC) formulations. Tramadol is marketed in the United States under the trade name Ultram immediate release tablet. Ultracet is a combination product containing tramadol and acetaminophen, is also marketed in the United States.
Company Coordinates stock-summary
Company Details
2 Gansevoort St Fl 9 , NEW YORK NY : 10014-1667
stock-summary
Tel: 1 781 6524500
stock-summary
http://www.avenuetx.com/
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."